Cancer Research Technology
Log in Register

1, 2, 3-triazole-derived androgen receptor antagonists (12a-f)

Invented at Deakin University


Catalogue Number 157777
Antigen/Gene or Protein Targets Androgen Receptors
Type Antitumoral
Relevance Prostate Cancer is the most commonly diagnosed cancer in men worldwide and is the fourth most common cancer diagnosed overall. Current treatments include castration, chemotherapy, radiation therapy and androgen blockade. Developing Androgen receptor antagonists falls under andogen blockade therapy. A common feature of AR Antagonists is the electron deficient 3,4-substituted aryl ring, and often consists of a trifluoromethyl group at the 3-position while a nitrile or nitro group is present at the 4-position. It can be a challenge to access aryl withdrawn N-phenyl amides via peptide coupling, providing moderate yields due to the nonnucleophilic anilinic nitrogen. Therefore, the inventors believe that replacement of the amide moiety of bicalutamide with a 1,2,3-triazole (accessed via very high yielding ‘click chemistry’) may have synthetic and biological value.

Replacing amides with 1,2,3-triazole is believed to show a number of benefits:
- Increasing synthetic yield
- Proving suitability of the 1,2,3-triazole as an isosteric replacement of the N-phenyl amide
- Minimising the peptidic nature of these compounds which can result in resistance to in vivo metabolism

The group present a number of novel androgen receptor antagonists which incorporate a 1,2,3-triazole replacement for the Nphenyl amide. The in silico docking of these compounds into the human androgen receptor (hAR) has been carried out, and their determined IC50 values for androgen responsive (LNCaP) and androgen independent (PC-3) cell lines has also been reported. The molecules 12a–f, possess promising anti-proliferative properties against LNCaP cells (IC50 34–45 lM) and PC-3 cells (IC50 29–151 lM).Information can be found in their publication PMID: 25301770.

These compounds present an excellent starting point for the development of prostate cancer therapeutics for both androgen dependent and independent forms of this disease.
Publication - PMID: 25301770.
Molecular Formula Panel includes the following:
12a: C19H14F4N4NaO3S+
12b: C18H15F4N4O5S+
12c: C20H21FN3O5S+
12d: C18H17FN3O5S+
12e: C19H16F3N4O3S+
12f: C18H16F3N4O5S+
Molecular Weight (g/mol) 12a: 477.0643 12b: 475.0713 12c: 434.1162 12d: 406.0835 12e: 437.089 12f: 457.0728
Research Area Cancer


There are 1 reference entries for this reagent.

View All References

References: 1 entry

Altimari et al. 2014. Bioorg Med Chem Lett. 24(21):4948-53. PMID: 25301770.

Add a reference

References: 1 entry

Altimari et al. 2014. Bioorg Med Chem Lett. 24(21):4948-53. PMID: 25301770.

Add a reference

Inventor Information

No inventors are currently linked to this reagent.

Add an inventor